These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19493073)

  • 1. Just a spoonful of sugar: drug safety for pediatric populations.
    Noah BA
    J Law Med Ethics; 2009; 37(2):280-91. PubMed ID: 19493073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Policy versus practice: comparison of prescribing therapy and durable medical equipment in medical and educational settings.
    Sneed RC; May WL; Stencel C
    Pediatrics; 2004 Nov; 114(5):e612-25. PubMed ID: 15520092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing controlled substance prescribing errors in a pediatric teaching hospital: an analysis of the safety of analgesic prescription practice in the transition from the hospital to home.
    Lee BH; Lehmann CU; Jackson EV; Kost-Byerly S; Rothman S; Kozlowski L; Miller MR; Pronovost PJ; Yaster M
    J Pain; 2009 Feb; 10(2):160-6. PubMed ID: 19010736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Children, drugs, and the Food and Drug Administration: studies of pediatric drugs are beginning to catch up.
    Ward RM
    Pediatr Ann; 2001 Apr; 30(4):189-94. PubMed ID: 11303433
    [No Abstract]   [Full Text] [Related]  

  • 5. Prescription practices of public and private health care providers in Attock District of Pakistan.
    Siddiqi S; Hamid S; Rafique G; Chaudhry SA; Ali N; Shahab S; Sauerborn R
    Int J Health Plann Manage; 2002; 17(1):23-40. PubMed ID: 11963441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Encouraging research and development of pediatric medical devices through legislative and regulatory action: the Pediatric Medical Device Safety and Improvement Act of 2007 in context.
    Bleicher EW
    Food Drug Law J; 2009; 64(3):531-64. PubMed ID: 19999642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies.
    Roberts R; Rodriguez W; Murphy D; Crescenzi T
    JAMA; 2003 Aug; 290(7):905-11. PubMed ID: 12928467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dental screening and referral of young children by pediatric primary care providers.
    dela Cruz GG; Rozier RG; Slade G
    Pediatrics; 2004 Nov; 114(5):e642-52. PubMed ID: 15520094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obtaining pediatric indications for new anti-epileptic drugs: how and when.
    Garofalo E
    Epilepsy Res; 2006 Jan; 68(1):38-42. PubMed ID: 16377135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoepidemiological research for the development and evaluation of drugs in pediatrics.
    Kaguelidou F; Durrieu G; Clavenna A
    Therapie; 2019 Apr; 74(2):315-324. PubMed ID: 30773345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Family pediatrics: report of the Task Force on the Family.
    Schor EL;
    Pediatrics; 2003 Jun; 111(6 Pt 2):1541-71. PubMed ID: 12777595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimates of pediatric medication use in the United States: current abilities and limitations.
    Lasky T
    Clin Ther; 2009 Feb; 31(2):436-45. PubMed ID: 19302916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription of methylphenidate to children and youth, 1990-1996.
    Miller AR; Lalonde CE; McGrail KM; Armstrong RW
    CMAJ; 2001 Nov; 165(11):1489-94. PubMed ID: 11762572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric oncology: regulatory initiatives.
    Hirschfeld S; Shapiro A; Dagher R; Pazdur R
    Oncologist; 2000; 5(6):441-4. PubMed ID: 11110594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Communicating uncertainties about prescription drugs to the public: a national randomized trial.
    Schwartz LM; Woloshin S
    Arch Intern Med; 2011 Sep; 171(16):1463-8. PubMed ID: 21911629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health and economic consequences of counterfeit drugs.
    Seiter A
    Clin Pharmacol Ther; 2009 Jun; 85(6):576-8. PubMed ID: 19451909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric cardiac devices--an FDA pediatrician's perspective of the challenges and potential solutions.
    Dolcimascolo F
    J Cardiovasc Transl Res; 2009 Jun; 2(2):147-9. PubMed ID: 20559980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
    Rose K
    Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA proposes new rules for off-label use of prescription drugs. Food and Drug Administration.
    Baker R
    BETA; 1998 Jul; ():8-9. PubMed ID: 11365570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.